DE-INCYTE
Incyte (Nasdaq: INCY) today announced that the Company will present key data from its oncology portfolio at the upcoming European Society of Medical Oncology (ESMO) Congress 2024, to be held September 13-17 in Barcelona and virtually.
"The data at ESMO underscore the progress across our oncology portfolio and the potential to impact patients where additional treatment options are needed. Notably, a Presidential Symposium will feature new, pivotal results from the Phase 3 POD1UM-303/InterAACT2 study of retifanlimab (Zynyz®) for the treatment of squamous cell anal carcinoma (SCAC). The POD1UM-303 data will support the supplemental Biologics License Application (sBLA) filing for retifanlimab in SCAC planned by year end 2024," said Pablo Cagnoni M.D., President, Head of Research and Development, Incyte. "We will also present new data on INCB123667, a potential first-in-class CDK2 inhibitor, which we believe has the potential to enhance outcomes and serve as a foundational treatment for platinum-resistant ovarian and other cancers."
Details on the abstracts accepted for presentation at ESMO include:
Presidential Symposium
Retifanlimab (PD-1)
POD1UM-303/InterAACT2: Phase 3 Study of Retifanlimab With Carboplatin-Paclitaxel (C-P) in Patients (Pts) With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal (SCAC) Not Previously Treated With Systemic Chemotherapy
Presidential Symposium I: Practice-changing trials. Presentation Number: LBA2. Presentation Time: 10:50-11:02 a.m. ET (4:50-5:02 p.m. CET), September 14, 2024
Mini Oral Session
INCB123667
Safety and Tolerability of INCB123667, a Selective CDK2 Inhibitor, in Patients (Pts) With Advanced Solid Tumors: A Phase 1 Study
Mini oral session: Developmental therapeutics. Presentation Number: 617MO. Presentation Time: 9:35 – 9:40 a.m. ET (3:35-3:40 p.m. CET), September 14, 2024
Conference Call and Webcast
Incyte will host an in-person analyst and investor event on Saturday, September 14, 2024, from 1:00-2:30 p.m. ET (7:00-8:30 p.m. CEST) to discuss key data presentations at ESMO including data from the POD1UM-303 Presidential Symposia and its CDK2 inhibitor program. The CDK2 data presentation will include new results from a later data cut-off, as well as the data included in the ESMO accepted abstract and mini-oral presentation. The event will be webcasted and can be accessed via the Events and Presentations tab of the Investor section of Incyte.com and it will be available for replay for 90 days.
Conference call details will be provided on the Investor section of Incyte.com.
Abstracts will be available to registered attendees on the ESMO Virtual Congress platform beginning on September 9, 2024. All accepted abstracts will be published in the ESMO Congress 2024 Abstract Book, a supplement to the official ESMO journal, Annals of Oncology.
More information regarding the 2024 ESMO Congress can be found at https://www.esmo.org/meeting-calendar/esmo-congress-2024.
About Retifanlimab (Zynyz®)
Retifanlimab (Zynyz®), is an intravenous PD-1 inhibitor indicated in the U.S. for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Zynyz is marketed by Incyte in the U.S. In 2017, Incyte entered into an exclusive collaboration and license agreement with MacroGenics, Inc. for global rights to retifanlimab.
Zynyz is a trademark of Incyte.
About Incyte
A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.
For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.
Incyte Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data from Incyte’s clinical development pipeline, the potential for retifanlimab and INCB123667 to positively impact patients and plans to submit an sBLA for retifanlimab in SCAC by year end 2024, contain predictions, estimates, and other forward-looking statements.
These forward-looking statements are based on our current expectations and are subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; determinations made by the FDA and regulatory agencies outside of the United States; the efficacy or safety of our products; the acceptance of our products in the marketplace; market competition; unexpected variations in the demand for our products and the products of our collaboration partners; the effects of announced or unexpected price regulation or limitations on reimbursement or coverage for our products; sales, marketing, manufacturing, and distribution requirements, including our ability to successfully commercialize and build commercial infrastructure for newly approved products and any additional new products that become approved; and other risks detailed from time to time in our reports filed with the U.S. Securities and Exchange Commission, including our annual report on Form 10-K and our quarterly report on Form 10-Q for the quarter ended June 30, 2024. We disclaim any intent or obligation to update these forward-looking statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240821420609/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Veeam and HPE Extend Strategic Partnership and Unveil Next-Gen Data Protection to Supercharge Enterprise Resilience3.12.2025 09:10:00 CET | Press release
Strategic Alliance Accelerates Hybrid Cloud Innovation and Eliminates Risk Across Modern Applications Veeam® Software, the #1 global leader by market share in Data Resilience, today announced a bold new chapter in its strategic alliance with HPE. Building on the partnership’s momentum earlier this year, HPE and Veeam are unleashing transformative, integrated solutions designed to empower enterprises with radically simplified data resilience for the modern enterprise. “Trust, resilience, and availability are the new currency of business,” said John Jester, Chief Revenue Officer at Veeam. “Our strengthened partnership with HPE gives customers the agility and confidence to protect, recover, and leverage their data, wherever it resides.” New innovations unveiled by Veeam and HPE include: Protection for HPE Morpheus VM Essentials Software: Veeam’s new native integration plug-in – now in beta with expected general availability in early 2026 – delivers hypervisor-based image-level backup for
Malaysia Digital Economy Corporation and Ant International Deepen Partnership to Accelerate Digitalisation of MSMEs Across Malaysia3.12.2025 07:00:00 CET | Press release
The Malaysia Digital Economy Corporation (MDEC) and Ant International are strengthening their partnership to accelerate the digital transformation of micro, small and medium enterprises (MSMEs) nationwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202701220/en/ (L-R) Chen Leiming, Senior Vice President & Chief Sustainability Officer of Ant International; Ir. Wan Murdani Wan Mohamad, Vice President of Digital Adoption, MDEC; Ian Cheong, CEO of EPOS In a newly established Memorandum of Understanding (MoU), Ant International will empower local MSMEs through EPOS, the all-in-one SME transformation platform of Ant International’s Antom, offering a comprehensive suite of digitalisation solutions. MDEC will support the programme by engaging the MSME community, industry associations, and ecosystem partners to drive broad-based digital adoption across the country. This builds on MDEC’s ongoing collaboration with Ant Internati
Hyatt Advances Luxury Brand Focus With New Leadership and Planned Global Expansion in 20263.12.2025 07:00:00 CET | Press release
Hyatt appoints Tamara Lohan to lead its luxury brands; shares preview of extraordinary openings worldwide. Hyatt Hotels Corporation (NYSE: H) today announced at ILTM Cannes the next chapter of Hyatt’s luxury journey, unveiling strengthened leadership with the appointment of Tamara Lohan as Global Brand Leader – Luxury on an interim basis and previewing a remarkable pipeline of luxury openings set for 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202423660/en/ Tamara Lohan, Global Brand Leader – Luxury, Hyatt “Hyatt’s momentum in luxury continues to accelerate, powered by our insights-driven development strategy and commitment to delivering deeply resonant guest experiences,” said Mark Hoplamazian, President and Chief Executive Officer, Hyatt. “Tamara brings world-class luxury expertise, and her leadership will further strengthen our ability to differentiate our luxury brands while growing with intent in the markets
Kioxia and Google Collaborate to Boost Clean Energy Use in Japan3.12.2025 03:30:00 CET | Press release
As part of its commitment towards a more sustainable future, Kioxia Corporation (“Kioxia”) today announced a collaborative initiative with Google LLC (“Google”) to boost its use of the clean electricity generated by a hydropower retrofit project in Japan's Chubu region. This project, owned by the Chubu Electric Power group, is expected to increase annual clean energy generation, contributing to the decarbonization of the grid and supporting both companies' net-zero efforts. Kioxia, a leader in memory solutions, has begun offtake of its portion of the hydropower project's electricity, which is expected to reach 160 gigawatt-hour (GWh) per year (enough to power about 40,000 Japanese homes). This move directly supports Kioxia's goals of sourcing 100% renewable energy for use in its own business activity by fiscal year (“FY”) 2040 and achieving net-zero greenhouse gas emissions by FY2050. Kioxia’s hydropower offtake, which provides “round-the-clock” clean power, also helps reduce Google's
NIKE, Inc. Announces Senior Leadership Changes to Accelerate “Win Now” Actions2.12.2025 22:59:00 CET | Press release
NIKE, Inc. (NYSE:NKE) today shared the following note with employees regarding changes to its Senior Leadership Team. // Team, I’d like to share some important changes to our Senior Leadership Team (SLT) that further remove layers and continue to bring us closer to athletes* and the marketplace. We’re establishing the role of EVP, Chief Operating Officer (COO), reporting to me, to better connect our operations and integrate technology more seamlessly into our sport offense. Venkatesh Alagirisamy (“Venky”), currently Chief Supply Chain Officer and a nearly 20-year Nike veteran, will take on this role effective December 8. Venky will lead Technology, in addition to his existing responsibilities leading Supply Chain, Planning, Operations, Manufacturing and Sustainability. He and his team will now be able to look end-to-end to ensure technology is fully integrated across the company and into how we create, plan, make, deliver and sell our world-class innovations across our three iconic bra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom